Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246

NCT00907803 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Orthopoxviral Disease

Interventions

DRUG: ST-246 400 mg
DRUG: ST-246 600 mg
DRUG: Placebo

Sponsor

SIGA Technologies

Collaborators

[object Object]